Dose modification for haematological toxicity: a survey of Australian medical oncologists

摘要: BACKGROUND: Evidence supporting dose modifications to reduce serious treatment-related adverse events of antineoplastic therapy is limited and frequently based on clinical trial protocols, which are not always generalisable community patients. eviQ an online resource with treatment protocols recommendations for modification formulated by expert opinion evidence-based review. Original recommended haematological thresholds delay were: neutrophil count <1.5 × 109 /L platelet <100 /L. AIMS: To evaluate the current practices Australian medical oncologists regard treatments, determine rates adherence recommendations. METHODS: An survey regarding was distributed over 400 Medical Oncology Group Australia members oncology reference committee via email. Responses were collated 18 December 2017. RESULTS: Of 153 respondents, 67% indicated that they did follow guidelines; 8% delayed curative intent at counts /L, compared 36% palliative treatment; most <1.0 (94% 97% respectively). 70% clinicians 34% treatment. No respondents original cut-off levels too aggressive. CONCLUSION: The majority responding guidelines, viewed as conservative. Subsequent this survey, reviewed updated